Physiological tests of small airways function in diagnosing asthma: a systematic review

Mohammed A Almeshari 1,2, Nowaf Y Alobaidi 1,3, Ross G Edgar 1, James Stockley 4, Elizabeth Sapey 1

ABSTRACT

Background Asthma is a common, heterogeneous disease that is characterised by chronic airway inflammation and variable expiratory airflow limitation. Current guidelines use spirometric measures for asthma assessment. This systematic review aimed to assess whether the most commonly reported tests of small airways function could contribute to the diagnosis of asthma.

Methods Standard systematic review methodology was used, and a range of electronic databases was searched (Embase, MEDLINE, CINAHL, CENTRAL, Web of Science, DARE). Studies that included physiological tests of small airways function to diagnose asthma in adults were included, with no restrictions on language or date. The risk of bias and quality assessment tools used were Agency for Healthcare Research and Quality tool for cross-sectional studies and Quality Assessment of Diagnostic Accuracy Studies 2 for diagnostic test accuracy (DTA) studies.

Results 7072 studies were identified and 10 studies met review criteria. 7 included oscillation techniques and 5 included maximal mid-expiratory flow (MMEF). Studies were small and of variable quality. In oscillometry, total resistance (R5) and reactance at 5 Hz (X5) was altered in asthma compared with healthy controls. The percentage predicted of MMEF was lower in patients with asthma compared with controls in all studies and lower than the % predicted forced expiratory volume in 1 s in DTA of oscillometry. R5 showed a sensitivity between 69% and 72% and specificity between 61% and 86%.

Conclusion There were differences in the results of physiological tests of small airway function in patients with asthma compared with controls. However, studies are small and heterogeneous. Further studies are needed to assess the effectiveness of these tests on a larger scale, including studies to determine which test methodology is the most useful in asthma.

Key messages

► Is there evidence to support the use of physiological tests of small airways function in the diagnosis of asthma?
► There is evidence of small airways dysfunction in asthma, which some physiological tests can identify. However, studies are small and heterogeneous and more studies are needed to understand the clinical utility of these tests.
► This systematic review provides a summary of the current evidence around physiological tests of small airways and asthma. It includes recommendations for the future work required to before the adoption of physiological small airways tests in the diagnosis of asthma.

BACKGROUND

Asthma is a common but heterogeneous disease characterised by chronic airway inflammation and clinically defined by the presence of respiratory symptoms that vary over time and in intensity. Physiologically, asthma is characterised by variable expiratory airflow limitation which may become persistent over time.1 Symptoms and airflow limitation can be extremely variable, including the age of onset, triggers for symptoms, the decline in lung function and therapeutic response.

It is estimated that 339 million people are affected by asthma globally but diagnosing asthma is often challenging as there is no gold standard test. This has led to a high burden of undiagnosed disease, especially in children and older adults.2 3 According to current guidelines, a diagnosis of asthma should be objectively supported with an assessment of forced expiratory volume in 1 s (FEV1) reversibility. However, some patients with asthma have no evidence of reversibility or airflow obstruction4 6 and airflow obstruction and reversibility are seen in patients with alternative diagnoses such as chronic obstructive pulmonary disease (COPD).7 8 Furthermore, the forced manoeuvres required for spirometry requires effort and coordination, which can be difficult for some individuals.9

In the past, asthma was thought to only affect larger airways10 but current evidence suggests that small airways (defined as airways of ≤2 mm in diameter) are affected as well. The small airways may form a site of active disease, even in the absence of airflow
obstruction. If the small airways are the first to be affected in asthma, identifying small airways dysfunction (SAD) may help identify asthma earlier, enabling treatment. However, there are a large number of tests that report small airways function. Some of these are being used as secondary outcomes in experimental studies of asthma, to determine asthma phenotype and assess the response to new therapies. The evidence to support the use of any physiological test of small airways function in the diagnosis of asthma is unclear.

This systematic review aimed to assess the evidence to support the use of commonly reported physiological tests of small airways function to diagnose asthma in adults, and assess if the selected tests should be included in future clinical studies of the disease.

METHODS

The protocol was prospectively registered in the international registry of systematic reviews (PROSPERO) with registration number CRD42019133239. The review was prepared in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA checklist is provided in online supplemental material file S1. Meta-analysis was considered where homogenous results were provided, otherwise data were pooled for graphical presentational purposes.

Through both scoping searches and discussion with experts, the following test were selected to be included in the search, forced oscillation technique (FOT), impulse oscillometry (IOS) and maximal mid-expiratory flow (MMEF) also known as forced expiratory flow between 25% and 75% of forced vital capacity (FVC) (FEF25–75%), and multiple breath washout test (MBW). These tests were selected as they represented some of the most commonly reported physiological tests of small airways function in obstructive lung disease in adults. Online supplemental figure S2 shows the Population, Intervention, Comparison and Outcome (PICO) chart with the studies selection criteria.

Eligibility criteria

Studies were considered for inclusion if they used one of the proposed physiological small airways function tests (FOT/IOS, MBW, MMEF) in diagnosing asthma in adults aged >18 years old. Patients with either a physician diagnosis or a suspected diagnosis of asthma were considered for inclusion. FEV1 was used as the comparator as it is the current standard in physiological airway assessment. Studies were excluded if they included only children (<18 years), patients with respiratory infections within 2 months of the assessment, did not assess FEV1, included patients with asthma-COPD overlap, were laboratory-based studies, animal-based studies or case series of less than 10 participants. There were no language or publication date restrictions.

Search queries were carried out in May 2019 (and the detailed search strategy is found in online supplemental material file S3) on the following electronic databases: Embase, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science (Abstracts and Proceedings) up to 5 years and DARE database for grey literature. Clinicaltrials.gov and EudraCT were also searched for active trials or published data. Hand searching of references listed in the selected articles was included. Search terms contained subject heading and terms for the selected test (IOS/FOT, MBW and MMEF) combined with terms of asthma and small airways function.

Study selection

Search results were imported into EndNote 9.1 (Clarivate Analytics) where duplicates were removed and data was uploaded to Rayyan (a webapp tool used for screening titles and abstracts). Abstracts were screened blindly and independently by the authors MA and NYA using the predefined inclusion and exclusion criteria. Disagreements were resolved by discussion, otherwise by the third reviewer, whose initials were RGE. Full-text articles were acquired and imported into EndNote 9.1 by author MA and similar abstract screening methodology was used in screening full texts for eligibility.

Data extraction

Data were extracted by author MA and checked by author NYA for consistency and accuracy using a custom, piloted data extraction form. Diagnostic criteria used to identify asthma, tests used to aid the diagnosis such as airway reversibility, asthma severity, phenotype, medications, the device used and comorbidities were extracted to aid narrative review and provide clinical context. Studies were categorised based on the small airways test used. In diagnostic test accuracy (DTA) studies, sensitivity and specificity values were extracted and a 2×2 contingency table was calculated.

Quality and risk of bias assessment

Quality and risk of bias were assessed using validated tools based on study design. Cross-sectional studies were assessed using the Agency for Healthcare Research and Quality (AHQR) checklist tool. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) was used in DTA. The QUADAS-2 tool assesses the risk of bias of studies over four domains: flow and timing, reference standard, index test and patient selection. The tool also assesses for applicability concerns under three domains: reference standard, index test and patient selection.

Descriptions of the tests of small airways function included in the reported studies

Here, only tests included in the analysed studies are described.
Oscillometry
Oscillometry can be assessed using either the FOT or IOS. Oscillometry transmits oscillating sound signals of various frequencies along the bronchial tree, providing a measure of the total airway resistance (resistance at 5 Hz (R5)) and the proximal airway resistance (resistance at 20 Hz (R20)), which allows for the derivation of small airways resistance (R5–R20). Reactance at 5 Hz (X5) relates to physical properties of the lung parenchyma and its ability to expand and facilitate alveolar filling. Resonant frequency (Fres) is the point at which reactance is zero (when forces of inertia and capacitance are equal). The area of reactance (AX) is the sum of area under the reactance curve between X5 and Fres. Limitations with this technique include the lack of universal normal ranges for all populations and variance of results between different devices, which can impede interpretation.

Maximum mid-expiratory flow
The MMEF is the mean forced expiratory flow between 25% and 75% of the FVC (FEF25–75%) and is taken from the spirometric blow with the largest sum of FEV1 and FVC. The MMEF is highly dependent on the validity of the FVC measurement and the level of expiratory effort. MMEF is commonly reported in studies of small airways as it is readily accessible from spirometry reports.

RESULTS
Study selection
Initial searches identified 7072 abstracts. After the removal of duplicates, 5764 abstracts were screened of which 469 abstracts included for full text screening. Ten articles ultimately met the inclusion criteria (Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram). Articles excluded in the full-text screening phase are described in online supplemental material file S4 with reasons given. All included studies were cross-sectional in design and 3/10 of the included studies were DTA studies.

Study characteristics
Seven of the included articles reported oscillometry (IOS/FOT) and five reported MMEF. None of the included studies reported MBW use in diagnosing asthma. Seven studies were not designed as DTA studies and are presented in Table 1. Three studies were designed as DTA studies and these are presented in Table 2. The diagnostic criteria used to confirm a diagnosis of asthma

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of included studies.
**Table 1** The characteristics of included studies without a diagnostic test accuracy analysis

<table>
<thead>
<tr>
<th>ID</th>
<th>Sample size</th>
<th>Age</th>
<th>BMI</th>
<th>SA device</th>
<th>SA function</th>
<th>FEV,</th>
<th>Diagnosis criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mendonça et al&lt;sup&gt;23&lt;/sup&gt; USA Cross-sectional</td>
<td>Asthma 35 Control 34</td>
<td>21 (3) 22 (2)</td>
<td>66 kg (12)* NR</td>
<td><strong>Asthma:</strong> MMEF% 69 (20) R8 cmH&lt;sub&gt;2&lt;/sub&gt;O 2.91 (0.99) <strong>Control:</strong> MMEF 93% (20) R8 cmH&lt;sub&gt;2&lt;/sub&gt;O 2.21 (0.48)</td>
<td>88 (11) 95 (10)</td>
<td>Previous diagnosis of asthma</td>
<td></td>
</tr>
<tr>
<td>Mori et al&lt;sup&gt;24&lt;/sup&gt; Japan Cross-sectional</td>
<td>Asthma 49 Control 13</td>
<td>53 (15) 42 (16)</td>
<td>23.9 (6.3) 21.2 (3.3) FOT-MostGraph-01</td>
<td><strong>Asthma:</strong> MMEF% 49.9 (27.7) X5 cmH&lt;sub&gt;2&lt;/sub&gt;O −0.96 (1.03) R5–R20 cmH&lt;sub&gt;2&lt;/sub&gt;O 0.86 (0.62) R5 cmH&lt;sub&gt;2&lt;/sub&gt;O 4.2 (1.43) <strong>Control:</strong> MMEF 88.9 (22.1) X5 cmH&lt;sub&gt;2&lt;/sub&gt;O −0.05 (0.27) R5–R20 cmH&lt;sub&gt;2&lt;/sub&gt;O 0.32 (0.44) R5 cmH&lt;sub&gt;2&lt;/sub&gt;O 3.29 (1.17)</td>
<td>80.5 (20.2) 105.4 (17.8)</td>
<td>GINA 2009</td>
<td></td>
</tr>
<tr>
<td>Mousa and Kamal&lt;sup&gt;25&lt;/sup&gt; Egypt Cross-sectional</td>
<td>Asthma 25 Control 20</td>
<td>45 (13) 34 (13)</td>
<td>29.27 (6.03) 26.6 (4.97) IOS-Masterscreen</td>
<td><strong>Asthma:</strong> R5% 245.24 (109.18) X5 (Unit NR) −2.87 (1.84) <strong>Control:</strong> R5% 109.25 (19.40) X5 (Unit NR) −0.28 (0.10)</td>
<td>59.98 (23.73) 89.75 (8.70)</td>
<td>GINA 2017</td>
<td></td>
</tr>
<tr>
<td>Koruga et al&lt;sup&gt;22&lt;/sup&gt; Serbia Cross-sectional</td>
<td>Asthma 31 Control 20</td>
<td>23 (5) NR IOS-Masterscreen</td>
<td><strong>Asthma:</strong> X5 kPa −0.09 (0.05) AX kPa 0.23 (0.16) R5 kPa 0.34 (0.09)</td>
<td>4.47 L (0.64)</td>
<td>Previous diagnosis of asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair et al&lt;sup&gt;26&lt;/sup&gt; UK Cross-sectional</td>
<td>Asthma 82 Control 61</td>
<td>49 (17) 28 (10)</td>
<td>NR IOS-Masterscreen</td>
<td><strong>Asthma:</strong> X5% 441.72 (137.86) R5% 162.22 (7.5) <strong>Control:</strong> X5% −229.8 (125.75) R5% 111.01 (3.96)</td>
<td>83.99 (2.23) 99.25 (1.72)</td>
<td>Previous diagnosis of asthma</td>
<td></td>
</tr>
<tr>
<td>Gulden et al&lt;sup&gt;20&lt;/sup&gt; Turkey Cross-sectional</td>
<td>Asthma 443 Control 229</td>
<td>37 (15) NR Vmax 229</td>
<td>MMEF L/s 3.17 (5.8)</td>
<td>2.99 (0.9)</td>
<td>GINA 2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Son et al&lt;sup&gt;31&lt;/sup&gt; Korea Cross-sectional</td>
<td>Asthma 125 Control 26</td>
<td>43 (1) NR NR</td>
<td>1. MMEF% 97.67 (3.48) 2. MMEF% 95.08 (5.74) 3. MMEF% 70.16 (4.64)</td>
<td>1. 107.84 (1.79) 2. 105.2 (3.43) 3. 96.16 (2.71)</td>
<td>Clinical suspicion of asthma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values reported in mean (SD).
*Weight in kg.
†Values reported in mean (SEM).
BMI, body mass index; FEV<sub>1</sub>, forced expiratory volume in 1 s; FOT, forced oscillation technique; GINA, Global Initiative for Asthma; ID, study identification (authors’ country, research type); IOS, impulse oscillometry; NR, not reported; SA, small airways.

differed among studies. Four studies used Global Initiative for Asthma guidelines,<sup>24</sup> <sup>25</sup> <sup>28</sup> <sup>30</sup> one American Thoracic Society guidelines<sup>27</sup> and one the global strategy: Joint Report of the National Institute for Heart, Lungs and Blood and WHO.<sup>20</sup> Three studies recruited patients based on a previous diagnosis of asthma, without reporting the diagnosis criteria used.<sup>22</sup> <sup>23</sup> <sup>26</sup> One study reported that patients with symptoms of asthma were included without any formal diagnosis.<sup>31</sup> All included studies were based in different countries (the USA, UK, Japan, Korea, Turkey, Egypt, Russia, Serbia, Iran and China) from four different continents (North America, Europe, Asia and Africa) making the ethnicity of participants heterogeneous. Body mass index (BMI) was only reported in three of the included studies.<sup>23</sup> <sup>25</sup> Meta-analysis of the data were inappropriate due to the variety and scope of methodological design. Where appropriate, data were displayed graphically to aid the representation of results. No MMEF studies explicitly corrected for FVC, which can potentially affect interpretation.

**Risk of bias**

Two risk of bias and quality assessment tools were used in this systematic review, based on the design of the included studies. Seven studies were assessed using the AHRQ tool for cross-sectional studies<sup>15</sup> (see figure 2A). This highlighted potential methodological issues around subject selection and quality assurance concerns, which may have impacted on the reliability of results and the
Open access reporting of study follow-up. There was an overall low risk of bias around patient recruitment (including the source of subjects), the inclusion/exclusion criteria, and the time periods when patients were identified. Response rates and completeness of results were all reported. A summary of all included studies using both tools is available in online supplemental material file S5.

Three studies were assessed using QUADAS-2 tool for DTA studies (see figure 2B). One study had a high risk of bias and applicability concern in the patient selection phase. Two studies had a high risk of bias in the index test.

Results of individual studies

Oscillometry

Seven studies used oscillometry. One study used FOT, and five studies used IOS. Two studies did not report which type of oscillometry was used. Five studies reported R5, which represent the total lung resistance. Only one study reported R5–R20. The values of the test were reported in different units with Mori et al. and Mendonça et al. reporting results in cmH2O/L/s, Nair et al. and Mousa and Kamal the % predicted values, and Koruga et al. and Nikkhah et al. in kPa/L/s.

Mori et al. reported R5, R5–R20, X5 and MMEF in 49 asthmatic patients, 13 controls and 51 COPD patients. They described differences in MMEF, R5–R20 and X5 when comparing asthma to control subjects but not R5. In addition, they reported that the coloured three-dimensional model provided by the FOT device could differentiate between asthma, COPD and healthy subjects, with a higher resistance and lower reactance observed in asthma. Asthma severity was not reported and 24 of the asthmatic subjects were ex-smokers.

Mendonça et al. studied 35 asthmatic and 31 non-asthmatic patients. They described differences in the whole-breath resistance at 8 Hz (R8) and the minimum resistance when comparing asthma to control subjects but not R5. They also described differences in MMEF, R5–R20 and X5 when comparing asthma to control subjects but not R5. In addition, they reported that the coloured three-dimensional model provided by the FOT device could differentiate between asthma, COPD and healthy subjects.

Table 2  The characteristics of included studies with a diagnostic test accuracy analysis

<table>
<thead>
<tr>
<th>ID</th>
<th>Sample size</th>
<th>Age</th>
<th>SA device</th>
<th>FEV1</th>
<th>SA test</th>
<th>Cut-off</th>
<th>TP</th>
<th>FN</th>
<th>FP</th>
<th>TN</th>
<th>Sens. %</th>
<th>Spc. %</th>
<th>Diagnosis criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al</td>
<td>Asthma 561</td>
<td>50.5 (18.8)*</td>
<td>MasterLab-IOS</td>
<td>NR</td>
<td>R5</td>
<td>X5</td>
<td>404</td>
<td>297</td>
<td>192</td>
<td>125</td>
<td>72</td>
<td>61</td>
<td>ATS guidelines</td>
</tr>
<tr>
<td>China</td>
<td>Control 205</td>
<td>37.6 (17.8)</td>
<td>MasterScreen-IOS</td>
<td>3.2 (0.9) L</td>
<td>R5</td>
<td>X5</td>
<td>404</td>
<td>297</td>
<td>192</td>
<td>125</td>
<td>72</td>
<td>61</td>
<td>ATS guidelines</td>
</tr>
<tr>
<td>Nikkhah et al</td>
<td>Asthma 87</td>
<td>41.4 (15.5)</td>
<td>MasterScreen-IOS</td>
<td>2.2 (0.6) L</td>
<td>R5</td>
<td>X5</td>
<td>60</td>
<td>27</td>
<td>12</td>
<td>75</td>
<td>69</td>
<td>86</td>
<td>GINA 2008</td>
</tr>
<tr>
<td>Iran</td>
<td>Control 87</td>
<td>37.6 (17.8)</td>
<td>MasterScreen-IOS</td>
<td>3.2 (0.9) L</td>
<td>R5</td>
<td>X5</td>
<td>60</td>
<td>27</td>
<td>12</td>
<td>75</td>
<td>69</td>
<td>86</td>
<td>GINA 2008</td>
</tr>
<tr>
<td>Iartsev</td>
<td>Asthma 209</td>
<td>1.474 (0.8)</td>
<td>Jaeger Master</td>
<td>1.101 (0.9)</td>
<td>MMEF</td>
<td>90%</td>
<td>138</td>
<td>74</td>
<td>1</td>
<td>0</td>
<td>216</td>
<td>99</td>
<td>Global strategy: Joint Report of the NHLBI and WHO 1993</td>
</tr>
<tr>
<td>Russia</td>
<td>Asthma 75</td>
<td>2.474 (0.9)</td>
<td>Jaeger Master</td>
<td>2.70 (0.73)</td>
<td>MMEF</td>
<td>70%</td>
<td>74</td>
<td>1</td>
<td>0</td>
<td>216</td>
<td>99</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Cross-sectional</td>
<td>Asthma 81</td>
<td>3.1 (1.6)</td>
<td>Jaeger Master</td>
<td>3.531 (1.6)</td>
<td>MMEF</td>
<td>50%</td>
<td>80</td>
<td>1</td>
<td>0</td>
<td>216</td>
<td>99</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Control 216</td>
<td>43.8 (0.8)</td>
<td>102.6 (1.4)</td>
<td>Jaeger Master</td>
<td>102.6 (1.4)</td>
<td>MMEF</td>
<td>50%</td>
<td>80</td>
<td>1</td>
<td>0</td>
<td>216</td>
<td>99</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

*For both groups.

ATS, American Thoracic Society; FEV1, forced expiratory volume in 1 s; FN, false negative; FP, false positive; GINA, Global Initiative for Asthma; ID, study identification (authors) country, research type; NHLBI, National Heart, Lung, and Blood Institute; NR, not reported; SA, small airways; Sen, sensitivity; Spc, specificity; TN, true negative; TP, true positive.
within the normal range. The authors examined the ability of MMEF, $R_{\text{min}}$, and $FEV_1$ to predict airway hyperresponsiveness to methacholine by producing a receiver operating characteristic (ROC) curve which showed that MMEF had the highest area under the curve (AUC) of 0.87, while $R_{\text{min}}$ and $FEV_1$ had AUC of 0.85 and 0.78, respectively. $R_8$ was not reported in the ROC curve.

Mousa and Kamal \(^{25}\) recruited 25 asthmatic patients and 20 healthy controls (with differences in the mean ages of the groups: asthmatic=45 years and the controls=34 years). Mean BMI did not differ between groups. The severity of the asthmatic group was not reported. IOS was used to assess asthma, with $X_5$ and $R_5$ being reported. $R_5$ was reported in % predicted, but the $X_5$ was reported in absolute values, but did not indicate the unit used. $X_5$ and $R_5$ were different between the two groups (asthma: mean $X_5$ −2.87±1.84 and $R_5$% 245.24±109.18. Healthy controls mean $X_5$ −0.28±0.10 and $R_5$% 109.25±19.40). $FEV_1$ was lower in the asthmatic group with a mean of 59.68%±23.73 predicted compared with the healthy controls mean of 89.75%±8.70 predicted.

Koruga \textit{et al}\(^{22}\) included 31 male military recruits in Serbia with a previous diagnosis of asthma. Histamine was used to assess bronchial hyperreactivity, recording the dose that decreased $FEV_1$ by 20% predicted value (PD20). $X_5$, $R_5$, and $Ax$ was reported at baseline and after PD20. They found that the overall change in $FEV_1$ after PD20 was 25.66%, while the $R_5$ and $X_5$ had a change of 66.64±62.91 and 132.18±148.13, respectively. No controls were included in the study.

Similar to Koruga \textit{et al}\(^{22}\) and Mousa and Kamal \(^{25}\) Nair \textit{et al}\(^{26}\) used a Masterscreen-IOS device, but reported $X_5$ and $R_5$ as % predicted values. Nair \textit{et al} included 82 patients with previous diagnosis of asthma and 61 healthy subjects. The asthma group was older (mean age 49 years vs mean age 28 years in the control group). Weight was not reported in either group. Nineteen per cent of the asthma patients were current or previous smokers, but the controls were all never smokers. All inhaled drugs such as short acting beta-agonists and long acting beta-agonists were withheld before reversibility testing except inhaled corticosteroids. Asthma severity and comorbidities were not reported. Airways reversibility was assessed using 400 µg of salbutamol via a metered dose inhaler and spacer and reported a mean change of 6.34% of $FEV_1$ in the asthma group and 2.25% in the healthy controls. The mean percentage of change after administering salbutamol was −33.78±4.43 and −72.93±88.73 in $R_5$ and $X_5$, respectively in the asthma group. In the control group, the mean change was −14.91±2.48 in $R_5$ and 40.09±65.64 in $X_5$.

Maximal mid-expiratory flow

Guldent Pasaoglu \textit{et al}\(^{30}\) recruited 433 asthmatic patients (mean age 37 years) and 152 patients with COPD (mean age 54 years), aiming to assess differences in clinical and spirometric features of asthma and COPD. 29% of the asthma group and 64% of the COPD group were current smokers. Reversibility was assessed in both groups using 200 µg of salbutamol and defined by an increase of more than 12% and 200 mL of the $FEV_1$ value. 62.1% of the asthma group met criteria for reversibility compared with 39.5% in the COPD group. MMEF was the only parameter that was below the normal range in non-smoking asthmatic patients with normal auscultation, suggesting that MMEF was a physiological marker of asthma in
non-smoking asymptomatic patients. Although bronchodilator responses were measured, these were not reported.

Son et al conducted a retrospective study of 125 patients with a clinical suspicion of asthma who had undergone an MCT. Patients were stratified into three groups based on their FEV₁ and MMEF response to MCT. The positive response to MCT was considered if there was a decline of 20% in FEV₁ and for MMEF, as well. Group 1 included patients with negative MCT tests for both parameters. Group 2 included patients with a negative FEV₁ and a positive MMEF. Group 3 included patients with positive tests to both parameters. The mean ages of the included subjects were 45 years in group 1, 39 years in group 2 and 43 years in group 3. Eight subjects had a previous diagnosis of asthma, three in group 1 and five in group 3. Allergic rhinitis was reported in 34 subjects, 16 of them were positive to MCT in both spirometric indices, therefore included in group 3. Mean baseline MMEF in groups 1 and 2 was 97.67%±3.48 predicted and 95.08%±5.74 predicted, respectively. In group 3, mean MMEF was 70.16%±4.64 predicted. The authors suggested that MMEF may be a more sensitive marker of asthma than FEV₁ in patients with otherwise normal spirometry results.

**DTA studies**

**Impulse oscillometry**

Li et al and Nikkhah et al assessed the DTA of IOS for asthma. The majority of participants in Nikkhah et al study were women, while Li et al had a majority of male participants. Neither study reported participants’ weight or BMI. Nikkhah et al cut-offs were not pre-specified, but were proposed after plotting an ROC curve. Li et al did not report a cut-off value. They both studied resistance at 5 Hz, but reactance was studied at different frequencies with Li et al at 35 Hz and Nikkhah et al at 5 Hz. The sensitivity of R₅ was reported as 72% by Li et al and 69% by Nikkhah et al while specificity reported by Li et al at 61% and Nikkhah et al at 86%. Reactance had lower sensitivity in both studies. Both studies did not report the asthma severity of the participants or clinical comorbidities and Li et al did not report the FEV₁ results, although they performed bronchodilator response tests on all participants. Figure 3A shows the pooled data of R₅ of the two studies.

**Maximal mid-expiratory flow**

There was only one DTA study which used MMEF in asthma compared with controls (Yartsev). The asthma group was older than the control group. Both the asthma and control groups had a majority of female participants. Asthma severity and comorbidities of participants were not reported. The author stratified asthma patients into three groups based on the baseline FEV₁. Group 1 included participants with FEV₁ of >80% predicted value, group 2 with FEV₁ 60%–80% predicted and group 3 with FEV₁ 25%–60% predicted. In MMEF tests, the cut-off used was 90% predicted in group 1, 70% predicted in group 2 and 50% predicted in group 3. The DTA of MMEF in group 1 was a sensitivity of 66% and specificity of 91%. Identical results were found in groups 2 and 3 with a sensitivity of 99% and specificity of 100%. The accuracy of MMEF was assessed on all groups with a cut-off value of 70% showed a sensitivity of 88% and specificity 97%. Using FEV₁, cut-off was set at 120% predicted in group 1, 90% predicted in group 2, 70% predicted in group 3. The DTA of FEV₁ in group 1 was a sensitivity of 77% and specificity of 65%. In groups 2 and 3, identical sensitivity of 100% and specificity of 100% was reported. All groups were assessed for accuracy using FEV₁, with a 70% predicted cut-off, showing a sensitivity of 92% and specificity of 88%. DTA data were pooled into the forest plot shown in figure 3B.

**Synthesis of results**

Small airways function in asthma were found to be different when compared with healthy controls. The % predicted MMEF value appeared consistently lower than the % predicted FEV₁, as shown in figure 4. In oscillometry, R₅ was also found to be consistently higher in asthmatic when compared with healthy controls as shown in figure 5. These results highlight the presence of small airways limitation in asthmatic patients with...
heterogeneous characteristics including age, ethnicity and weight.

**Risk of bias across studies**

There were some concerns of bias in regard to reporting outcomes. Kamal and Mousa\textsuperscript{25} reported R5 as the % predicted value while X5 was reported without a unit of measurement. Iartsev\textsuperscript{29} did not report how the cut-offs were determined or how subjects were recruited.

**DISCUSSION**

To the authors’ knowledge, this is the first systematic review to assess the use of physiological tests of small airways function in the diagnosis of asthma. Previous work has suggested that SAD is associated with asthma and that the prevalence of SAD increases with the severity of asthma.\textsuperscript{32,33} This review suggests that most published studies of small airways function tests in asthma are heterogeneous, of varying methodological quality and have primarily identified SAD rather than using measures of small airways to diagnose asthma. No studies reported the severity of asthma in the participants and participants groups were often poorly matched or characterised in terms of other comorbidities and weight.

This review focuses on MMEF and oscillometry and does not explore all potential measures to assess small airways function. MMEF and oscillometry were chosen as these represented the most commonly cited small airways measures. The clinical utility of oscillometry techniques has been described in asthma and other lung conditions such as interstitial lung diseases and COPD.\textsuperscript{19} Oscillometry has been suggested as a useful tool in diagnosing asthma in children.\textsuperscript{34} However, there remains a lack of universal reference ranges, especially in adults. Height\textsuperscript{23} and sex\textsuperscript{35} appear to alter values. Oostveen \textit{et al.}\textsuperscript{35}

**Figure 4** Comparison of % predicted of MMEF to FEV\textsubscript{1} in asthmatic patients. FEV\textsubscript{1}, forced expiratory volume in 1 s; MMEF, maximal mid-expiratory flow.

**Figure 5** Comparison of R5 between asthmatic patients to healthy controls.
conducted a multicentre study on healthy subjects in an effort to produce reference ranges for oscillometry in adults, but only one ethnicity was studied. Another study was also conducted in Japan to establish reference ranges for Japanese adults. Understanding and interpreting oscillometry remains challenging. In this review, it was unclear if oscillometry studies provided the most robust measure of small airways function. The R5–R20 (often referred to as resistance of the small airways) was only reported by Mori et al. Airways reversibility, a hallmark of asthma, was only assessed using oscillometry by Nair et al and, here, the mean percentage change in the FEV1 in the asthmatic group was 6.34%, which is less than the standard reversibility change of 12%.

The MMEF is an effort-dependent test and guidelines for reproducibility of the manoeuvre are based on FVC and FEV1. In all the included articles that studies MMEF, the % predicted of MMEF was found to be lower in asthmatic groups compared with control groups. Moreover, the % predicted value of MMEF was lower than the % predicted FEV1 in the asthmatic group, suggesting that small airways limitation might be an early marker of airways obstruction. The potential utility of MMEF in early disease was described in one study of patients with alpha-1 antitrypsin deficiency, where an MMEF less than 80% predicted, with a normal FEV1/FVC ratio, was associated with increased respiratory symptoms and a faster decline in FEV1 compared with those with an MMEF of 80% or greater and normal spirometry, suggesting a role for MMEF in early disease monitoring.

There are significant limitations to the evidence base described in this review including study heterogeneity, poor patient characterisation and differences in reported values. Not all tests of small airways function have been assessed in asthma (eg, MBW). There are no universally accepted predicted values for oscillometry, especially in adults, making the interpretation of the results more difficult. Oscillation techniques produce many parameters in both inspiratory and expiratory phases and the differences in reported values limits comparisons between studies. MMEF was not corrected for FVC in any study, and this is a limitation as MMEF is a timed/flow measurement and FVC exhalation curve changes may affect the results. Nevertheless, most studies provide at least some signal of SAD in asthma suggesting these indices could be helpful in diagnosing and monitoring asthma. To take this field forward, further research is needed. This should include standardising the assessment of small airways tests (although different tests may have greater or lesser utility in different diseases) and forming normal reference ranges to aid interpretation. Studies in asthma need to predefine how asthma was diagnosed, and report clearly which small airways tests have been measured, by what device, what units are reported and what would be considered an abnormal result or clinically meaningful change in a specified value.

**CONCLUSION**

Physiological tests of small airways function are feasible in diagnosing asthma and have been shown to be altered in asthma when compared with healthy adults. However, a lack of robust reference ranges and the heterogeneity of approach complicate their use.

Further studies are needed to assess small airways function in asthma, especially in early disease. Larger studies are needed to assess the impact of demographic characteristics and comorbidities such as obesity or allergic rhinitis. This systematic review of current literature suggests these tests may have promise as part of the future diagnostic criteria of asthma, but more work is needed before they can be embedded into clinical care.

**Correction notice** The license type of the paper has changed from CC BY-NC to CC BY.

**Contributors** MA and ES conceived, planned and analysed the data, and made a major contribution in writing the manuscript. MA, NYA and RGE performed abstract screening, full-text screening and quality assessment. MA and RGE planned and performed searching strategy and data synthesis. RGE and JS contributed to data analysis and writing the manuscript. All authors have read and approved the manuscript.

**Funding** This systematic review was part of a funded PhD by King Saud University, Riyadh, Saudi Arabia under the aegis of the Government of Saudi Arabia.

**Competing interests** ES reports grants from MRC, grants from Wellcome Trust, grants from NHR, grants from British Lung Foundation, grants from HDR-UK, outside the submitted work. RGE reports grants from NHR, grants from Chest Foundation, grants from Alpha 1 Foundation, outside the submitted work. All other authors report no conflict of interest.

**Patient consent for publication** Not required.

**Data availability statement** All data relevant to the study are included in the manuscript or uploaded as supplementary information. All the included data has been obtained from the included peer-reviewed articles.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/

**ORCID iDs**

Mohammed Almeshari http://orcid.org/0000-0001-8449-9491
Noway Y Aloabaidi http://orcid.org/0000-0002-0609-5771
Ross Edgar http://orcid.org/0000-0002-5971-3335
Elizabeth Sapey http://orcid.org/0000-0003-3454-5482

**REFERENCES**

## PRISMA 2009 Checklist

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
<td>1</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.</td>
<td>2</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
<td>4</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
<td>5</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and registration</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.</td>
<td>5</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.</td>
<td>6</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.</td>
<td>6</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.</td>
<td>S.3</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).</td>
<td>6</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.</td>
<td>6</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
<td>6</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
<td>7</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
<td>n/a</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.</td>
<td>n/a</td>
</tr>
</tbody>
</table>
# PRISMA 2009 Checklist

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias across studies</td>
<td>15</td>
<td>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).</td>
<td>7</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>16</td>
<td>Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>RESULTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study selection</td>
<td>17</td>
<td>Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.</td>
<td>8</td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.</td>
<td>8</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>19</td>
<td>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).</td>
<td>9</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>20</td>
<td>For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.</td>
<td>9</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>21</td>
<td>Present results of each meta-analysis done, including confidence intervals and measures of consistency.</td>
<td>14</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>22</td>
<td>Present results of any assessment of risk of bias across studies (see Item 15).</td>
<td>14</td>
</tr>
<tr>
<td>Additional analysis</td>
<td>23</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>DISCUSSION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary of evidence</td>
<td>24</td>
<td>Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).</td>
<td>15</td>
</tr>
<tr>
<td>Limitations</td>
<td>25</td>
<td>Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).</td>
<td>15</td>
</tr>
<tr>
<td>Conclusions</td>
<td>26</td>
<td>Provide a general interpretation of the results in the context of other evidence, and implications for future research.</td>
<td>17</td>
</tr>
<tr>
<td><strong>FUNDING</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>27</td>
<td>Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.</td>
<td>1</td>
</tr>
</tbody>
</table>


For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org)
# PICO Table

<table>
<thead>
<tr>
<th><strong>Population</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults &gt;18 years old with asthma or clinical suspicion of asthma</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Intervention</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physiological tests small airways function</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Comparator</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Outcome</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of asthma</td>
<td></td>
</tr>
</tbody>
</table>

PICO chart with details of study selection criteria.
Medline:

1. exp Asthma/
2. exp Bronchial Spasm/
3. exp Bronchial Hyperreactivity/ or exp Respiratory Hypersensitivity/
4. exp Airway Resistance/ or exp Bronchoconstriction/
5. airway reactivity.ab,ti.
6. exp Respiratory Function Tests/
7. small airway*.ab,ti.
8. distal airway*.ti,ab.
9. MMEF.mp.
10. fef25*.mp.
11. FOT.mp.
12. Forced Oscillatory.mp.
13. Impulse Oscillatory.mp. or exp Oscillometry/
15. Impulse Oscillimatry.mp.
16. Impulse Oscillation.mp.
17. (IOS and airway*).mp.
18. exp Nitric Oxide/ and asthma.mp.
19. Fractional expired nitric oxide.ti,ab.
20. Fractional exhaled nitric oxide.ti,ab.
21. FeNO.ti,ab.
22. (FeNO and asthma).ti,ab.
23. multiple breath washout.mp.
24. MBW.ti,ab.
25. MBW.ti,ab. and airway*.mp.
26. exp Spirometry/
27. (Reversibility and asthma).ti,ab.
28. exp Respiratory Function Tests/
29. exp Peak Expiratory Flow Rate/
30. exp Asthma/
31. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
32. 26 or 27 or 28 or 29
33. adult*.mp.
34. 1 or 2 or 3 or 4 or 5
35. 30 and 31 and 32 and 33 and 34
36. Diagnos*.ti,ab.
37. 35 and 36

Results: 1856
EMBASE:

1. exp asthma/
2. exp bronchospasm/
3. exp bronchus hyperreactivity/
4. Respiratory Hypersensitivity.mp.
5. exp airway resistance/
6. exp bronchoconstriction/
7. airway reactivity.ab,ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp lung function test/
10. small airway*.ab,ti.
11. distal airway*.ti,ab.
12. MMEF.mp.
13. fef25*.mp.
14. FOT.mp.
15. Forced Oscillatory.mp.
16. Impulse Oscillatory.mp. or exp Oscillometry/
17. Impulse Oscillatory.mp.
18. Impulse Oscillimetry.mp.
19. Impulse Oscillation.mp.
20. (IOS and airway*).mp.
21. exp Nitric Oxide/ and asthma.mp.
22. Fractional expired nitric oxide.ti,ab.
23. Fractional exhaled nitric oxide.ti,ab.
24. (FeNO and asthma).ti,ab.
25. multiple breath washout.ti,ab.
26. MBW.ti,ab. and airway*.mp.
27. exp spirometry/
28. (Reversibility and asthma).ti,ab.
29. exp lung function test/
30. exp peak expiratory flow/
31. exp asthma/
32. adult*.mp.
33. diagnos*.ti,ab.
34. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
35. 27 or 28 or 29 or 30
36. 8 and 31 and 32 and 33 and 34 and 35

Results: 2553
Web Of Science:
TS=(Asthma OR bronchospasm OR bronchus hyperreactivity OR Respiratory Hypersensitivity OR airway resistance OR bronchoconstriction OR airway reactivity)
AND
TS=(lung function test OR small airway* OR distal airway* OR Pulmonary function OR PFT OR MMEF OR fef25* OR FOT OR Forced Oscillatory OR Impulse Oscillatory OR Oscillometry OR Impulse Oscillimetry OR Impulse Oscillation OR IOS OR Nitric Oxide OR Fractional expired nitric oxide OR Fractional exhaled nitric oxide OR FeNO OR multiple breath washout OR MBW)
AND
TS=(Spirometry OR Reversibility OR lung function test* OR peak expiratory flow OR PEF*)
AND
TS=(Adult*)
AND
TS=(Diagnos*)

Up to 5 years = 975
CENTRAL (Cochrane)

#1 Asthma OR bronchospasm OR bronchus hyperreactivity OR Respiratory Hypersensitivity OR airway resistance OR bronchoconstriction OR airway reactivity
#2 lung function test OR small airway* OR distal airway* OR Pulmonary function OR PFT OR MMEF OR fef25* OR FOT OR Forced Oscillatory OR Impulse Oscillatory OR Oscillometry OR Impulse Oscillimetry OR Impulse Oscillation OR IOS OR Nitric Oxide OR Fractional expired nitric oxide OR Fractional exhaled nitric oxide OR FeNO OR multiple breath washout OR MBW
#3 Spirometry OR Reversibility OR lung function test* OR peak expiratory flow OR PEF*
#4 adult*
#5 diagnos*
#6 #1 AND #2 AND #3 AND #4 AND #5

Results: 813
CINAHL:
S1  (MH "Asthma+")
S2  (MM "Bronchial Spasm")
S3  TI bronchospasm OR AB bronchospasm
S4  "bronchus hyperreactivity"
S5  "bronchus hyperreactivity"
S6  TI bronchus hyperreactivity OR AB bronchus hyperreactivity
S7  TI bronchus hyperreactivity OR AB bronchus hyperreactivity
S8  (MH "Respiratory Hypersensitivity+")
S9  (MM "Airway Resistance")
S10 TI airway resistance OR AB airway resistance
S11 (MM "Bronchoconstriction")
S12 "airway reactivity"
S13 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S14 (MH "Respiratory Function Tests+")
S15 TI small airway* OR AB small airway*
S16 TI distal airway* OR AB distal airway*
S17 TI MMEF OR AB MMEF
S18 TI fef25* OR AB fef25*
S19 TI FOT OR AB FOT
S20 TI MMEF OR AB MMEF AND airway*
S21 TI Forced Oscillatory OR AB Forced Oscillatory
S22 TI Impulse Oscillimetry OR AB Impulse Oscillimetry
S23 TI Impulse Oscillimetry OR AB Impulse Oscillimetry
S24 TI Impulse Oscillation OR AB Impulse Oscillation
S25 TI (IOS and airway*) OR AB (IOS and airway*)
S26 AB (Nitric Oxide AND asthma) OR TI ((Nitric Oxide AND asthma)
S27 AB (feno AND asthma) OR TI (feno AND asthma)
S28 TI multiple breath washout OR AB multiple breath washout
S29 "MBW"
S30 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
S31 (MM "Spirometry") OR (MM "Airway Resistance") OR (MH "Respiratory Airflow+") OR (MH "Forced Expiratory Flow Rates+") OR (MM "Peak Expiratory Flow Rate")
S32 "diagnos*"
S33 S1 AND S13 AND S30 AND S31 AND S32
S34 (MH "Asthma+")
S35 (MM "Bronchial Spasm")
S36 TI bronchospasm OR AB bronchospasm
S37 "bronchus hyperreactivity"
S38 "bronchus hyperreactivity"
S39 TI bronchus hyperreactivity OR AB bronchus hyperreactivity
S40 TI bronchus hyperreactivity OR AB bronchus hyperreactivity
S41 (MH "Respiratory Hypersensitivity+")
S42 (MM "Airway Resistance")
S43 TI airway resistance OR AB airway resistance
S44 (MM "Bronchoconstriction")
S45 "airway reactivity"
S46 S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45
S47 (MH "Respiratory Function Tests+")
S48 TI small airway* OR AB small airway*
S49 TI distal airway* OR AB distal airway*
S50 TI MMEF OR AB MMEF
S51 TI fef25* OR AB fef25*
S52 TI FOT OR AB FOT
S53 TI MMEF OR AB MMEF AND airway*
S54 TI Forced Oscillatory OR AB Forced Oscillatory
S55 TI Impulse Oscillimetry OR AB Impulse Oscillimetry
S56 TI Impulse Oscillimetry OR AB Impulse Oscillimetry
S57 TI Impulse Oscillation OR AB Impulse Oscillation
S58 TI (IOS and airway*) OR AB (IOS and airway*)
S59 AB (Nitric Oxide AND asthma) OR TI ((Nitric Oxide AND asthma)
S60 AB (feno AND asthma) OR TI (feno AND asthma)
S61 TI multiple breath washout OR AB multiple breath washout
S62 "MBW"
S63 S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62

Results: 875

Total Before duplicates removal = 7072
Excluded Articles.

<table>
<thead>
<tr>
<th>Reason of Exclusion</th>
<th>Citations Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Wrong Outcome</td>
<td>1-264</td>
</tr>
<tr>
<td>B. Wrong Population</td>
<td>265-304</td>
</tr>
<tr>
<td>C. Wrong Study Design</td>
<td>305-368</td>
</tr>
<tr>
<td>D. Abstracts Only</td>
<td>369-446</td>
</tr>
<tr>
<td>E. Review articles</td>
<td>447-449</td>
</tr>
<tr>
<td>F. Duplicates</td>
<td>450-457</td>
</tr>
</tbody>
</table>

A. (1-264)  
B. (265-304)  
C. (305-368)  
D. (369-446)  
E. (447-449)  
F. (450-457)


34. Byrne AL, Marais BJ, Mitnick CD, et al. Asthma and atopy prevalence are not reduced among former tuberculosis patients compared with controls in Lima, Peru. BMC Pulm Med. 19(40).


< or = 16 ppb better than FENO < or =12 ppb to rule out mild and moderate to severe asthma [added]. Respir Res. 2009;10(15):15.


434. Sharifi A, Nazemiyeh M. Methacholine challenge test with impulse oscillometry versus spirometry: Which is more sensitive in detecting airway hyper-responsiveness (AHR?). Eur Respir J. 2018;52.


443. Van Nederveen-Bendien SA, Heijerman HGM, Van Den Ende-Van Der Velden PJW. Specific airway resistance is more sensitive in diagnosing asthma in patients with a normal bronchial challenge test (FEV1) compared to FeNO and blood eosinophils. Allergy: European Journal of Allergy and Clinical Immunology. 2010;92:546.


### Risk of Bias

<table>
<thead>
<tr>
<th></th>
<th>Patient Selection</th>
<th>Index Test</th>
<th>Reference Standard</th>
<th>Flow and Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al. 2015</td>
<td>![Unclear]</td>
<td>![Low]</td>
<td>![Low]</td>
<td>![Low]</td>
</tr>
<tr>
<td>Nikkhah et al. 2011</td>
<td>![High]</td>
<td>![Unclear]</td>
<td>![Low]</td>
<td>![Unclear]</td>
</tr>
<tr>
<td>Yartsev 2006</td>
<td>![Low]</td>
<td>![Low]</td>
<td>![Low]</td>
<td>![Low]</td>
</tr>
</tbody>
</table>

### Applicability Concerns

<table>
<thead>
<tr>
<th></th>
<th>Patient Selection</th>
<th>Index Test</th>
<th>Reference Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al. 2015</td>
<td>![Unclear]</td>
<td>![Low]</td>
<td>![Low]</td>
</tr>
<tr>
<td>Nikkhah et al. 2011</td>
<td>![High]</td>
<td>![Unclear]</td>
<td>![Low]</td>
</tr>
<tr>
<td>Yartsev 2006</td>
<td>![Low]</td>
<td>![Low]</td>
<td>![Low]</td>
</tr>
</tbody>
</table>

**QUADAS-2 Summary**
<table>
<thead>
<tr>
<th>Study</th>
<th>Define the source of information</th>
<th>List inclusion and exclusion criteria for exposed and unexposed subjects or refer to previous publications</th>
<th>Indicate whether or not subjects were consecutive if not population-based</th>
<th>Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants</th>
<th>Describe any assessments undertaken for quality assurance purposes</th>
<th>Explain any patient exclusions from analysis</th>
<th>Describe how confounding was assessed and/or controlled</th>
<th>Summarize patient response rates and completeness of data collection</th>
<th>Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gulden et al. 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koruga et al. 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mendonça et al. 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mori et al. 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mousa &amp; Kamal 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair et al. 2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Son et al. 2009</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AHRQ Summary